多西他赛联合奈达铂治疗PF方案耐药复发转移鼻咽癌的临床观察

目的:评价多西他赛联合奈达铂治疗对PF方案耐药复发、转移晚期鼻咽癌的初步疗效及其毒副反应,探讨治疗鼻咽癌的二线化疗方案.方法:诊断明确的转移、放疗后复发且对PF方案耐药的晚期鼻咽癌患者45例,奈达铂80 mg/m2,静脉滴入,d1；多西他赛75 mg/m2,静脉滴入,d2,每3周重复.化疗2个周期后根据WHO制定的实体瘤客观疗效评价标准和抗癌药物毒性分级(0～Ⅳ)标准评价疗效和不良反应.结果:45例患者共完成142个周期化疗,每例患者化疗周期数2～6个,中位化疗周期数为3个.完全缓解(CR)2例,部分缓解(PR)24例,稳定(SD)13例,进展(PD)6例,总有效率为57.8％(26/45).1年生存率为66.7％(30/45).毒副反应主要表现为脱发,粒细胞和血小板、血色素中轻度减少,其余毒副反应较少.结论:多西他赛联合奈达铂治疗对PF方案耐药的晚期鼻咽癌有效率高,不良反应可以耐受,是治疗晚期鼻咽癌较好的二线化疗方案.

Clinical observation of combination of taxotere and nedaplatin in the treatment of PF regimen resistant metastatic and recurrent nasopharyngeal carcinoma

OBJECTIVE:To evaluate the effectiveness and side effects of the combination of docetaxel and nedaplatin in the treatment of PF regimen resistant metastatic and recurrent nasopharyngeal carcinoma.METHODS: Forty-five patients with metastatic and recurrent nasopharyngeal carcinoma after treatment were enrolled.They were all failed to the treatment by Cisplatin and 5-fluorouracil(PF).The treatment regimen include nedaplatin 80 mg/m2,d1,and taxotere 75 mg/m2,d2.Cycles were repeated every 3 weeks The treatment effects were evaluated by WHO criterion every 2 cycles and toxicities were evaluated by Common Toxicity Criteria(CTC) Version 3.0.RESULTS:Totally 142 cycles of chemotherapy were conducted in 45 patients.Patient received 2-4 cycles with average of 3 cycles.Complete response(CR) was observed in 2 patients,Partial response(PR) in 24 patients,Stable disease(SD) in 13 patients and Progression disease(PD) in 6 patients result in total response rate of 57.8%(26/45) and 1 year survival rate of 66.7%(30/45).The main toxicity were mild alopecia,neutropenia,thrombocytopenia and anemia.Other tixicities were very rare.CONCLUSION: Combination of docetaxel and nedaplatin is an ffective regimen in the treatment of metastatic and recurrent nasopharyngeal carcinoma who are failed to PF regimen.It’s an effective and tolerable second-line chemotherapy.